Markets
Iran Conflict Sends Stocks Tumbling: Is This a Buying Opportunity or a Sign of More Pain Ahead?
Markets shed 600+ points as Middle East tensions spike oil prices above $90. Here's how to position your portfolio.
James McAllister • March 12, 2026
Earnings
VRTX: Is Vertex Pharmaceuticals a Safe Haven in a Turbulent Market?
Vertex's 4% surge on kidney drug trial results highlights why long-term investors are finding shelter in this biotech gi…
Catherine Walsh • Mar 12
IPO
SpaceX IPO: Watch the Breakout, But Don't Chase the Hype
SpaceX eyes record Nasdaq listing with fast-track index inclusion. Traders see momentum, but valuation risks loom large.
Tyler Brooks • Mar 12
Economy
Fed's Rate Pause: What Does it Mean for Your Portfolio and the US Economy?
The Fed held rates at 3.5-3.75%, but sticky inflation at 2.4% and geopolitical risks warrant caution for investors.
Diana Kowalski • Mar 12
Free Newsletter
Informed positions start with informed mornings.
Market-moving analysis and institutional-grade research, complimentary and delivered daily.
More Stories
Earnings
Oracle's AI Gambit Pays Off: Is ORCL a Must-Have Stock for the Long-Term Investor?
Marcus Rivera • Mar 12, 2026
Markets
Navigating the Geopolitical Storm: How Traders Can Profit from Market Volatility Amid Iran Conflict
James McAllister • Mar 12, 2026
SPAC Analysis
SUMAU's $150M Debut: Why Patient Investors Should View SPACs as Market Infrastructure, Not Momentum Plays
Catherine Walsh • Mar 11, 2026
IPO
SpaceX IPO Alert: The Setup is Forming for a Record-Breaking Breakout
Tyler Brooks • Mar 11, 2026
Economic Policy
The Fed's Dangerous Waiting Game: Why Higher-for-Longer Rates Meet an Oil Shock
Diana Kowalski • Mar 11, 2026